» Articles » PMID: 12355068

Integrated Genomic and Epigenomic Analyses Pinpoint Biallelic Gene Inactivation in Tumors

Overview
Journal Nat Genet
Specialty Genetics
Date 2002 Oct 2
PMID 12355068
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrant methylation of CpG islands and genomic deletion are two predominant mechanisms of gene inactivation in tumorigenesis, but the extent to which they interact is largely unknown. The lack of an integrated approach to study these mechanisms has limited the understanding of tumor genomes and cancer genes. Restriction landmark genomic scanning (RLGS; ref. 1) is useful for global analysis of aberrant methylation of CpG islands, but has not been amenable to alignment with deletion maps because the identity of most RLGS fragments is unknown. Here, we determined the nucleotide sequence and exact chromosomal position of RLGS fragments throughout the genome using the whole chromosome of origin of the fragments and in silico restriction digestion of the human genome sequence. To study the interaction of these gene-inactivation mechanisms in primary brain tumors, we integrated RLGS-based methylation analysis with high-resolution deletion maps from microarray-based comparative genomic hybridization (array CGH; ref. 3). Certain subsets of gene-associated CpG islands were preferentially affected by convergent methylation and deletion, including genes that exhibit tumor-suppressor activity, such as CISH1 (encoding SOCS1; ref. 4), as well as genes such as COE3 that have been missed by traditional non-integrated approaches. Our results show that most aberrant methylation events are focal and independent of deletions, and the rare convergence of these mechanisms can pinpoint biallelic gene inactivation without the use of positional cloning.

Citing Articles

Gene expression patterns of the developing human face at single cell resolution reveal cell type contributions to normal facial variation and disease risk.

Khouri-Farah N, Winchester E, Schilder B, Robinson K, Curtis S, Skene N bioRxiv. 2025; .

PMID: 39868299 PMC: 11761091. DOI: 10.1101/2025.01.18.633396.


Concurrent RB1 and P53 pathway disruption predisposes to the development of a primitive neuronal component in high-grade gliomas depending on MYC-driven EBF3 transcription.

Pagani F, Orzan F, Lago S, De Bacco F, Prelli M, Cominelli M Acta Neuropathol. 2025; 149(1):8.

PMID: 39821672 DOI: 10.1007/s00401-025-02845-y.


SOCS1 expression in cancer cells: potential roles in promoting antitumor immunity.

Ilangumaran S, Gui Y, Shukla A, Ramanathan S Front Immunol. 2024; 15:1362224.

PMID: 38415248 PMC: 10897024. DOI: 10.3389/fimmu.2024.1362224.


The Tumor Suppressor SOCS1 Diminishes Tolerance to Oxidative Stress in Hepatocellular Carcinoma.

Shukla A, Khan M, Cayarga A, Namvarpour M, Chowdhury M, Levesque D Cancers (Basel). 2024; 16(2).

PMID: 38254783 PMC: 10814246. DOI: 10.3390/cancers16020292.


Data Mining Suggests That CXCL14 Gene Silencing in Colon Cancer Is Due to Promoter Methylation.

Wang Y, Wang S, Niu Y, Ma B, Li J Int J Mol Sci. 2023; 24(22).

PMID: 38003215 PMC: 10671198. DOI: 10.3390/ijms242216027.